Abstract
Brain atrophy caused by neuronal loss is a prominent pathological feature of Alzheimers disease (AD). Amyloid (A ), the major component of senile plaques, is considered to play a central role in neuronal cell death. In addition to removal of the toxic Aβ , direct suppression of neuronal loss is an essential part of AD treatment; however, no such neuroprotective therapies have been developed. Excess amount of Aβ evokes multiple cytotoxic mechanisms, involving increase of the intracellular Ca2+ level, oxidative stress, and receptor-mediated activation of cell-death cascades. Such diversity in cytotoxic mechanisms induced by Aβ clearly indicates a complex nature of the AD-related neuronal cell death. We have identified a 24-residue peptide, Humanin (HN), which suppresses in vitro neuronal cell death caused by all AD-related insults, including Aβ , so far tested. The anti-AD effect of HN has been further confirmed in vivo using mice with Aβ -induced amnesia. Altogether, such potent neuroprotective activity of HN against AD-relevant cytotoxicity both in vitro and in vivo suggests the potential clinical applications of HN in novel AD therapies aimed at controlling neuronal death.
Keywords: Alzheimer's disease, neuronal death, amyloid, amyloid precursor protein (APP), presenilin (PS), Humanin (HN), neuroprotection
Current Neuropharmacology
Title: Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin
Volume: 4 Issue: 2
Author(s): Takako Niikura, Hirohisa Tajima and Yoshiko Kita
Affiliation:
Keywords: Alzheimer's disease, neuronal death, amyloid, amyloid precursor protein (APP), presenilin (PS), Humanin (HN), neuroprotection
Abstract: Brain atrophy caused by neuronal loss is a prominent pathological feature of Alzheimers disease (AD). Amyloid (A ), the major component of senile plaques, is considered to play a central role in neuronal cell death. In addition to removal of the toxic Aβ , direct suppression of neuronal loss is an essential part of AD treatment; however, no such neuroprotective therapies have been developed. Excess amount of Aβ evokes multiple cytotoxic mechanisms, involving increase of the intracellular Ca2+ level, oxidative stress, and receptor-mediated activation of cell-death cascades. Such diversity in cytotoxic mechanisms induced by Aβ clearly indicates a complex nature of the AD-related neuronal cell death. We have identified a 24-residue peptide, Humanin (HN), which suppresses in vitro neuronal cell death caused by all AD-related insults, including Aβ , so far tested. The anti-AD effect of HN has been further confirmed in vivo using mice with Aβ -induced amnesia. Altogether, such potent neuroprotective activity of HN against AD-relevant cytotoxicity both in vitro and in vivo suggests the potential clinical applications of HN in novel AD therapies aimed at controlling neuronal death.
Export Options
About this article
Cite this article as:
Niikura Takako, Tajima Hirohisa and Kita Yoshiko, Neuronal Cell Death in Alzheimers Disease and a Neuroprotective Factor, Humanin, Current Neuropharmacology 2006; 4 (2) . https://dx.doi.org/10.2174/157015906776359577
DOI https://dx.doi.org/10.2174/157015906776359577 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Estrogen Receptor Polymorphisms: Significance to Human Physiology, Disease and Therapy
Recent Patents on DNA & Gene Sequences Chondroitin Sulfate Glycosaminoglycans for CNS Homeostasis-Implications for Material Design
Current Medicinal Chemistry Non-Pharmacological Treatments for ADHD in Youth
Adolescent Psychiatry Mini-Mental Parkinson (MMP) as a Dementia Screening Test: Comparison with the Mini-Mental State Examination (MMSE)
Current Aging Science Overview on the Tricks of HIV Tat to Hit the Blood Brain Barrier
Current HIV Research Mechanisms of Cortical Neural Synchronization Related to Healthy and Impaired Consciousness: Evidence by Quantitative Electroencephalographic Studies
Current Pharmaceutical Design T Cell-based Therapies for Atherosclerosis
Current Pharmaceutical Design Circulating Biochemical Markers of Brain Damage in Infants Complicated by Ischemia Reperfusion Injury
Cardiovascular & Hematological Agents in Medicinal Chemistry Cognitive Impairment in the Septic Brain
Current Neurovascular Research Saving the Ischemic Penumbra: Potential Role for Statins and Phosphodiesterase Inhibitors
Current Vascular Pharmacology The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences
Recent Patents on Biotechnology Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition High Throughput Binding Analysis Determines the Binding Specificity of ASF/SF2 on Alternatively Spliced Human Pre-mRNAs
Combinatorial Chemistry & High Throughput Screening Pharmacogenetics of Angiotensin-Converting Enzyme Inhibitors in Patients with Alzheimer's Disease Dementia
Current Alzheimer Research Insights from Mouse Models to Understand Neurodegeneration in Down Syndrome
CNS & Neurological Disorders - Drug Targets Dietary Fat Intake and Risk of Alzheimer’s Disease and Dementia: A Meta-Analysis of Cohort Studies
Current Alzheimer Research QSAR, Docking, and CoMFA Studies of GSK3 Inhibitors
Current Pharmaceutical Design In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
CNS & Neurological Disorders - Drug Targets The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies